For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
UCB announced an additional upgrade to its FY25 financial guidance, where it now expects revenue to exceed € 7.6b, representing +24% y/y (previously at least € 7b), and adj. EBITDA margin to be higher than 31% (previously at least 30%). This is the company's second guidance upgrade this year and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS, as well as a favourable payer m...
MEETING OF THE SUPERVISORY BOARD OF UNIBAIL-RODAMCO-WESTFIELD N.V. Amsterdam, December 4, 2025 Press Release MEETING OF THE SUPERVISORY BOARD OF UNIBAIL-RODAMCO-WESTFIELD N.V. On December 4, 2025, the Supervisory Board of Unibail-Rodamco-Westfield N.V. (“URW NV”) met and took note of the resignation of the Chairman and Member of the Supervisory Board, Mr. Jean-Marie Tritant, who will resign as of December 31, 2025. URW NV announces that Mr. Vicent Rouget is designated as temporary replacement as Chairman and member of the Supervisory Board effective as of January 1, 2026. Mr. Rouget wi...
URW SE - Information on total number of voting rights and shares in the share capital as at November 30, 2025 Paris, December 3rd, 2025 Information on total number of voting rights and shares in the share capital as of November 30th, 2025 (Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the AMF) DateTotal number of shares in the capitalTotal number of voting rights30/11/2025143,334,100143,334,100 UNIBAIL-RODAMCO-WESTFIELD SEA European Company with Management Board and Supervisory BoardShare capital: €716,670,500Registered office: 7 place du...
URW SE - Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 30 novembre 2025 Paris, le 3 décembre 2025 Informations relatives au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 (articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’AMF) DateNombre total d’actions composant le capitalNombre total de droits de vote30/11/2025143 334 100143 334 100 UNIBAIL-RODAMCO-WESTFIELD SESociété Européenne à Directoire et Conseil de surveillanceau capital de 716 670 500 euros Siè...
URW appoints Kathleen Verelst as Chief Investment Officer Paris, December 3, 2025 Press release URW appoints Kathleen Verelst as Chief Investment Officer Unibail-Rodamco-Westfield (“URW”, “the Group”) announces that at its meeting today the Supervisory Board, upon the recommendation of its Governance, Nomination and Remuneration Committee (“GNRC”), decided the appointment of Kathleen Verelst as Chief Investment Officer (CIO) and a member of its Management Board, effective January 1, 2026. Kathleen has more than 30 years of global real estate experience, working for a leading internati...
A director at Atos SE bought 1,101 shares at 45.000EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
A director at Novo Nordisk AS bought 6,450 shares at 312.500DKK and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.